
Immunocore promotes non-executive to chairman
pharmafile | November 19, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | immunocore, knowles
Oxford-based biotech firm Immunocore has appointed Dr Jonathan Knowles as the new executive chairman of its Board of directors.
Knowles succeeds Nicholas Cross who was in the role since the company was founded in 2008, and who will remain on the Board as deputy chairman.
Knowles has been a non-executive director of Immunocore since 2010 and was formerly president of Group Research, and a member of the executive committee at Roche for 12 years.
Knowles also served as a Board member at Genentech for over ten years and was also at Chugai Pharmaceuticals in Japan. Prior to joining Roche in 1997 he was a research director at Glaxo Wellcome.
James Noble, chief executive of Immunocore said: “We are extremely fortunate to have appointed someone of Jonathan’s calibre as the executive chairman of the Immunocore Board. His willingness to commit to Immunocore is a great testament to the potential of our company.”
Knowles added: “I am delighted to have been appointed as the new chairman and look forward to working more closely with my Board colleagues and the rest of the team at Immunocore to grow the company, creating novel agents that we hope will contribute significantly to curing cancer.”
Related Content

AstraZeneca loses two senior executives as biotechs appoint new CEOs
Two of AstraZeneca’s senior executives have been poached by the biotech firms Ironwood Pharmaceuticals and …

Lilly and Immunocore collaborate on melanoma
Eli Lilly is teaming up again with UK biotech Immunocore in order to work together …

AstraZeneca signs immuno-oncology deal with UK firm
UK pharma and biotech firms AstraZeneca and Immunocore are teaming up to launch early-stage studies …






